FDA Clearance Update for U.S. In-Vitro Diagnostics Market

Molecular Designs Receives First FDA 510(k) Clearance for Flu A, Flu B and RSV Molecular Panel

BIRMINGHAM, United States — November 14, 2026 — Molecular Designs, a developer of molecular infectious disease assays, announced on Friday that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance (K262789) for its SimplicityDx Panel FluA/FluB/RSV, the company’s first FDA-cleared assay. The clearance adds a new multiplex respiratory option to the U.S. In-Vitro Diagnostics Market. 

The panel is a multiplex real-time RT-PCR test. It qualitatively detects and differentiates RNA from influenza A, influenza B and respiratory syncytial virus (RSV) in anterior nasal swab specimens from people with signs and symptoms of respiratory tract infection. Results are intended as an aid in differential diagnosis, alongside other clinical, epidemiologic and laboratory findings.

The test is for prescription use only and for laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity tests. It includes an internal control and is designed to work with the company’s Simplicity Dx Extraction products.

The company stated that influenza and RSV often circulate at the same time, and that respiratory season can stretch laboratory capacity. Testing for all three viruses in a single run is intended to help laboratories keep pace during those months.

The U.S. in-vitro diagnostics market was valued at USD 25.54 billion in 2023 and is projected to reach USD 32 billion by 2030, at a CAGR of 2.9% from 2024 to 2030, according to Next Move Strategy Consulting (NMSC).

Key Highlights:

• The FDA 510(k) clearance (K262789) is the first for a Molecular Designs assay.

• The panel detects and differentiates influenza A, influenza B and RSV in a single run from anterior nasal swabs.

• The test is limited to prescription use in CLIA-certified, high-complexity laboratories.

• Its breakaway format lets laboratories use only the tests needed for each run, with minimal pipetting. It also supports batch processing on higher-volume days.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, high costs associated with research, development and regulatory approval remain a significant restraint in the U.S. in-vitro diagnostics market. Companies must meet stringent standards set by agencies such as the FDA.

NMSC analysts note that point-of-care testing is expected to be a significant driver of demand in the coming years. It complements laboratory-based testing in settings where immediate results are required.

Industry Outlook:

Molecular diagnostics, including PCR-based testing, is one of the technique segments tracked within the U.S. in-vitro diagnostics market, alongside immunoassays and clinical chemistry. Respiratory panels that run in laboratory workflows continue to be a focus area for assay developers ahead of and during seasonal circulation of influenza and RSV.

NMSC projects the market will reach USD 32 billion by 2030. Regulatory approval requirements and the integration of point-of-care testing with traditional laboratory diagnostics are among the factors shaping that outlook.

Source: News-Medical

For More Information: Download FREE Sample on U.S. In-Vitro Diagnostics Market Report 

Prepared By: Sanyukta Deb